Cytosolic inhibitor of Nrf2 (INrf2) is an adaptor protein that mediates ubiquitination/degradation of NF-E2-related factor 2 (Nrf2), a master regulator of cytoprotective gene expression. In this paper, we demonstrate that INrf2 degrades endogenous antiapoptotic B-cell CLL/lymphoma 2 (Bcl-2) protein and controls cellular apoptosis. The DGR domain of INrf2 interacts with the BH2 domain of Bcl-2 and facilitates INrf2:Cul3-Rbx1-mediated ubiquitination of Bcl-2 by the conjugation of ubiquitin molecules to lysine17 of Bcl-2. Further studies showed that INrf2 enhanced etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis. Antioxidants antagonized Bcl-2:INrf2 interaction, led to the release and stabilization of Bcl-2, increased Bcl-2:Bax heterodimers and reduced apoptosis. Moreover, dysfunctional/mutant INrf2 in human lung cancer cells failed to degrade Bcl-2, resulting in decreased etoposide and UV/c radiation-mediated DNA fragmentation. These data provide the first evidence of INrf2 control of Bcl-2 and apoptotic cell death, with implications in antioxidant protection, survival of cancer cells containing dysfunctional INrf2, and drug resistance.
The NF-E2-related factor 2 (Nrf2):cytosolic inhibitor of Nrf2 (INrf2) complex serves as a sensor of chemical/radiationinduced oxidative/electrophilic stress. 1 Nrf2 resides predominantly in the cytoplasm, where it interacts with INrf2 (inhibitor of Nrf2) or Keap1 (Kelch-like ECH-associated protein).
1 INrf2 functions as an adaptor protein for Cul3-Rbx1-dependent degradation of Nrf2. The N-terminal BTB domain of INrf2 binds to Cul3-Rbx1, whereas the C-terminal Kelch (DGR) domain interacts with Nrf2 and facilitates Nrf2 ubiquitination and degradation, resulting in the repression of Nrf2-dependent gene expression. [2] [3] [4] Oxidative or electrophilic stress generated from chemicals or radiation modifies reactive cysteines of INrf2 (C151, C272, and C288), followed by PKCd-mediated phosphorylation of Nrf2S40, which leads to dissociation of Nrf2 from INrf2 and increased transcription of Nrf2-dependent genes. [5] [6] [7] The induction of Nrf2 downstream genes encodes cytoprotective proteins that neutralize reactive molecules, eliminate damaged macromolecules, reduce inflammation, and restore cellular redox homeostasis. 8, 9 Nrf2 is switched 'ON' in response to stress by mechanisms as described above. Nrf2 is switched 'OFF' once the stress subsidizes by a distinct mechanism. Tyrosine kinase Fyn phosphorylates Nrf2Y568, leading to nuclear export and degradation of Nrf2. 10, 9 The switching 'ON' and 'OFF' of Nrf2 protects cells and promotes cell survival.
INrf2-null mice demonstrated persistent accumulation of Nrf2 in the nucleus that led to postnatal death from malnutrition resulting from hyperkeratosis in the esophagus and forestomach. 11 Reversed phenotype of INrf2 deficiency by breeding with Nrf2-null mice suggested that tightly regulated negative feedback might be essential for cell survival. 8 The systemic analysis of INrf2 genomic locus in human lung-cancer patients and cell lines showed that deletion, insertion, and missense mutations in functionally important domains of INrf2 result in reduction of INrf2 affinity for Nrf2 and elevated expression of cytoprotective genes. 12, 13 Unrestrained activation of Nrf2 in cells increases the risk of adverse effects, including survival of damaged cells, tumorigenesis, and drug resistance. 9 Therefore, it appears that cells contain mechanisms that autoregulate cellular abundance of Nrf2.
14 In other words, Nrf2 induces transcription of INrf2 for self-destruction.
Structural and functional analyses of INrf2 have identified a Kelch (DGR) domain, which interacts with several proteins. Although Nrf2 is a well-known substrate for INrf2, the DGR domain of INrf2 has been reported to bind other proteins including Nrf1, prothymosin-a, fetal Alz clone 1, and IKKb. [15] [16] [17] [18] It is noteworthy that binding of a protein with the INrf2 DGR region does not always lead to degradation of the protein. Recently, we have shown that prothymosin-a interacts with the DGR domain of INrf2 and this interaction is required for nuclear localization of INrf2. 1 Therefore, INrf2 and its interacting partners have several different roles in cell signaling and survival.
The B-cell CLL/lymphoma 2 (Bcl-2) family of proteins regulates cell death and survival. 19, 20 Bcl-2 proteins are central regulators of caspase activation, and have a key role in cell death by regulating the integrity of the mitochondrial and endoplasmic reticulum membranes. 21, 22 The Bcl-2 family of proteins is classified into three subfamilies. The Bcl-2 subfamily includes Bcl-2, Bcl-xL, and Bcl-w, all of which exert anticell death activity and share sequence homology, particularly within four regions, BH (Bcl-2 homology) 1-4 domains. The Bax subfamily consists of Bax and Bak, which contain BH1, BH2, and BH3 homology domains but lack the BH4 domain and are proapoptotic. The Bik subfamily that includes Bik and Bid contains only the BH3 domain and lack BH1, BH2, and BH3 domains. Bik members are proapoptotic. One of the important features of Bcl-2 proteins is that they have the ability to form homodimers and heterodimers. The life or death of a cell may be determined by the Bcl-2 family of proteins in two ways, either through heterodimerization between antiapoptotic and proapoptotic members, or through the independent functions of these proteins. In either case, the ratio between antiapoptotic and proapoptotic members of the Bcl-2 family may determine the susceptibility of a cell to apoptosis.
In this report we demonstrate a novel mechanism of the control of Bcl-2 and apoptotic cell death. We show that the INrf2:Cul3-Rbx1 complex ubiquitinates Bcl-2 lysine17 residue and degrades Bcl-2. Specifically INrf2, through its DGR region, interacts with the BH2 domain of Bcl-2 and facilitates Bcl-2 ubiquitination and degradation. We also show that INrf2-mediated degradation of Bcl-2 leads to decreased Bcl-2:Bax heterodimers, resulting in an increased level of Bax, and subsequently enhanced etoposide and radiation (UV/g)-mediated apoptosis in cancer cells. We further show that antioxidants antagonize INrf2:Bcl-2 interaction, leading to the stabilization of Bcl-2 and cell survival.
Results
INrf2 mediates ubiquitination and degradation of antiapoptotic factor Bcl-2. Flag-INrf2-HEK293 cells expressing tetracycline-inducible Flag-INrf2 were developed. Immunoprecipitation of INrf2 with Flag antibody, followed by mass spectrometry analysis, revealed that Flag-INrf2 interacted with antiapoptotic protein Bcl-2 (Supplementary Figure S1) . Therefore, we investigated the role of INrf2 in control of Bcl-2 and apoptotic cell death. The transfection of mouse hepatoma (Hepa-1) cells with small interfering (si)RNA showed dose-dependent silencing of INrf2 expression (Figure 1a ). The silencing of INrf2 led to a dose-dependent increase in Bcl-2 and decrease in proapoptotic protein Bax (Figure 1a ). In the same experiment, the level of Nrf2 also increased as expected (Figure 1a) . In a related experiment, overexpression of INrf2-V5 protein in Hepa-1 cells showed INrf2-V5-dependent decrease in Bcl-2 and Nrf2 protein levels, and increase in Bax (Figure 1b) . Next, we determined the effect of siRNA-mediated inhibition and cDNA-derived overexpression of INrf2 on Bcl-2 transcription ( Figure 1c (Figure 2c ). The analysis of mouse Bcl-2 amino acid sequence showed the presence of only four lysine residues at amino acid positions 17, 22, 214, and 236 that were found to be highly conserved in humans and rats (Figure 2d ). Mouse Bcl-2K17, K22, K214, and K236 were individually mutated to alanine to identify the target lysine(s) of INrf2-mediated ubiquitination. Wild-type and mutant Bcl-2 were analyzed for endogenous INrf2-mediated degradation and ubiquitination in Hepa-1 cells Figure S3a and b) . Further, the Bcl-2 protein consists of four unique BH domains that include BH4, BH3, BH1, and BH2, and a transmembrane domain (TMD) (Figure 3f ). We generated Bcl-2 deletion mutants deficient in the various BH domains to investigate which BH domain of Bcl-2 is required for interaction with INrf2 (Figure 3f (Figure 3g , middle and right panels). All other Bcl-2 deletion mutants showed interaction with INrf2-V5. These results suggested that the BH2 domain of Bcl-2 is required for Bcl-2 interaction with INrf2. This conclusion was further supported with point mutations of the BH2 domain of Bcl-2. The BH2 domain is highly conserved among human, mouse, rat, and chicken Bcl-2 proteins (Figure 3h ). The alignment of the Bcl-2 BH2 domain from different species also showed that tryptophane185 and double glycine190/191 are conserved across species (Figure 3h) . We generated two mutations, W185A and double glycine mutant G190AG191A of Bcl-2, and their interaction with Flag-INrf2 was examined. The results demonstrate that wild-type Bcl-2 and Bcl-2W185A mutant interacted with Flag-INrf2 ( Figure 3i) ; however, double glycine mutant Bcl-2G190AG191A demonstrated significantly reduced interaction with Flag-INrf2 in both Hepa-1 and HEK293 cells (Figure 3i , right panels). These observations supported our results from the deletion mutants that the BH2 domain of Bcl2 is required for INrf2 interaction (Figure 3i) Overexpression of INrf2 decreases the Bcl-2-Bax complex. The BH1 and BH2 domains of Bcl-2 heterodimerize with Bax to exert its antiapoptotic action. 23 We conducted experiments to investigate whether INrf2 disturbs the Bcl-2:Bax complex through degradation of Bcl-2. One set of cells was further treated with tBHQ (50 mM) for an additional 24 h. The cytoplasmic histone-associated DNA fragments (mono and oligonucleosomes) were quantified using a Cell Death Detection ELISA kit (Roche) and plotted. (c) MTT Cell survival assay. A549 or A549-INrf2-C2 cells were treated with etoposide or exposed to UV or g radiation and cell survival was measured by MTT assay as described in Materials and methods. (d) Clonogenic cell survival assay. A549, A549-C1, A549-C2 cells were grown to 70% confluence and exposed to DMSO or different concentrations of etoposide (1-40 mM) for 48 h. Cells were treated with trypsin and 1000 cells were re-seeded in 100 mm tissue culture dishes (in triplicate) and incubated for 9 days. A freshly prepared clonogenic reagent was added to the plates and blue colonies were counted. The experiment was repeated twice. Each data point represents a mean±S.D. and was normalized to the value of the corresponding control cells carrying mutant INrf2G333C showed accumulation of Nrf2 and are resistant to drugs. 13 Glycine333 residue is present in the first Kelch (DGR) domain of INrf2 to which Bcl-2 binds as shown earlier in this study. This raised interesting questions regarding the capacity of mutant INrf2G333C to bind and degrade Bcl-2. Two clones (A549-C-1 and A549-C-2) expressing wild-type INrf2 were generated. Immunoblot analysis of HBE4, A549, A549-C-1, and A549-C-2 cells is shown in Figure 7a (Figure 7b ). In addition, A549 cells expressing endogenous mutant INrf2 exposed to UVB and g radiation showed significantly (B2.2-fold) lower DNA fragmentation compared with A549-C-2 cells expressing endogenous mutant and cDNA-derived wildtype INrf2 (Figure 7b , middle and lower panels). Further, A549 cells showed increased (B20-30%) cell survival compared with the A549-C2 clone when exposed to drug or radiation (Figure 7c ). In addition, we compared the relative cell survival in A549, A549-C-1, and A459-C-2 cells by clonogenic cell survival assay after treatment of cells with different concentrations of etoposide. The data demonstrate that A549-C-1 and A549-C-2 cells show 35 and 40% reduction in cell survival, respectively, compared with A549 cells (Figure 7d ). These data together suggest that point mutation in the DGR region of INrf2 reduced INrf2 interaction with Bcl-2, resulted in stabilization of Bcl-2, decreased drug or UV/g radiation-induced DNA fragmentation, and promoted cell survival.
Discussion
We demonstrated that INrf2 directly interacts with Bcl-2 and functions as an adaptor protein for Cul3-Rbx1-mediated ubiquitination of Bcl-2-lysine17 residue and degradation of Bcl-2. Domain-mapping studies demonstrated that the DGR domain of INrf2 and the BH2 domain of Bcl-2 were required for their interaction. Overexpression of INrf2 led to degradation of Bcl-2 and decreased Bcl-2:Bax heterodimers. The treatment of INrf2-overexpressing cells with etoposide upregulated Bax protein, induced cytochrome c release from mitochondria, activated caspase-3/7, and led to increased apoptotic cell death. In other words, increase in INrf2 promoted apoptosis by degrading Bcl-2. On the other hand, antioxidant treatment antagonized INrf2:Bcl-2 interaction, led to stabilization of Bcl-2, increased interaction of Bcl-2 with Bax, and decreased etoposide-mediated cellular apoptosis. Together, these results concluded that INrf2 regulates apoptotic cell death by controlling antiapoptotic protein Bcl-2. It is noteworthy that INrf2 is known to bind to PGAM5, which binds to Bcl-xL. 24 Therefore, the role of INrf2 in regulation of Bcl-xL through PGAM5 in apoptosis is also expected but remains unknown.
The mechanism of dissociation of Bcl-2 from INrf2 remains unknown. However, it is possible that oxidative/electrophilic modification of INrf2C151 and phosphorylation of Bcl-2 are required for the dissociation of Bcl-2 from INrf2. This assumption is based on INrf2:Nrf2 studies. 7, 9 Our data showed that antioxidants increased Bcl-2S70 phosphorylation. The role of this phosphorylation in the release of Bcl-2 from INrf2 is possible but remains unknown. It is noteworthy that Bcl2S70 phosphorylation is required for heterodimerization with Bax and cell survival. [25] [26] [27] The release of Bcl-2 from INrf2 and prevention of apoptosis are presumably important mechanisms that protect cells from dying in acute stress. Once the exposure effect subsides, the level of Bcl-2 protein is brought back to normal.
Recent studies have reported increased stabilization/ accumulation of Nrf2 because of mutations in INrf2, resulting in loss of function in lung and breast tumors. 12, 13, 28, 18 The lung cancer cell line A549 contains the INrf2G333C mutant protein that has lost its capacity to bind/degrade Nrf2, leading to accumulation of Nrf2. 13 It has been suggested that higher levels of Nrf2 in A549 cells might have contributed to the survival of these cells in lung cancer. Our studies demonstrate that INrf2G333C mutant is also incapable of binding/degrading Bcl-2 and this must also have contributed to the survival of A549 cells. This is also supported by observations from this study that expression of wild-type INrf2 in A549 cells reduced Bcl-2 and increased etoposide-mediated apoptosis. The present studies also demonstrated that Bcl-2 accumulation and reduced apoptosis in lung cancer A549 cells containing mutant INrf2 protein contributed to drug (etoposide) or radiation resistance.
In conclusion, INrf2 functions as an adaptor for the Cul3-Rbx1-mediated ubiquitination and degradation of Bcl-2 as depicted in a model (Supplementary Figure S7) . INrf2 under normal conditions facilitates Cul3-Rbx1-mediated ubiquitination and degradation of Bcl-2. This contributes to the maintenance of normal level of Bcl-2:Bax heterodimers and apoptosis. Oxidative/electrophilic stresses lead to dissociation of Bcl-2 from INrf2, causing cellular levels of Bcl-2 to increase. This leads to an increase in Bcl-2:Bax heterodimers, a decrease in Bax, reduced apoptosis, enhanced cell survival, and drug resistance.
Materials and methods
Plasmid constructs. A full-length mouse INrf2 coding sequence (1872 bp) and various deletion domains of INrf2 were cloned into GFP vector as described earlier. 1 We also amplified various deletions of the DGR region of INrf2 by PCR and cloned into DDGR-INrf2-GFP constructs. Mouse Bcl-2 cDNA purchased from Addgene (Cambridge, MA, USA) was subcloned into pcDNA3.1/V5-His/Topo vector and also into pcmx-Flag vector. We constructed Flag-DBH4-Bcl-2, Flag-DBH3-Bcl-2, Flag-DBH2-Bcl-2, and Flag-DBH1-Bcl-2 deletion domains of Bcl-2 using two steps, PCR and ligation. V5-tagged Bcl2K17A, Bcl-2K22A, Bcl-2K214A, Bcl-2K236A, Bcl-2W185A, and Bcl-2G190AG191A mutants were generated by using a Gene Tailor site-directed mutagenesis Kit (Invitrogen, Carlsbad, CA, USA).
